000538 Yunnan Baiyao GroupWatchlist
Yunnan Baiyao Group News
Yunnan Baiyao (000538): Stable performance in the third quarter and continued improvement in profitability
Incident Yunnan Baiyao released its third quarter report. In the first three quarters of 2023, the company achieved total operating income of 29.689 billion yuan, +10.30% year-on-year; net profit of 4.123 billion yuan, +78.90% year-on-year; non-return
Yunnan Baiyao (000538.SZ): R&D investment of 219 million yuan in the first three quarters increased 5.17% year-on-year
Gelonghui, November 15|Yunnan Baiyao (000538.SZ) recently said in receiving a survey from institutional investors that in the first three quarters of 2023, the company invested 219 million yuan in R&D, an increase of 5.17% over the previous year. In terms of building R&D capacity, the company set up an R&D management committee to manage the overall R&D system, using the R&D ideas of inheriting the essence of Yunnan traditional Chinese medicine, empowering health product upgrades, careful layout of innovative drugs, and AI-assisted drug design to carry out unified resources and efficient management of resources. At the same time, the R&D project formulation and licensing system is scientifically clear, and diversification and advantage focus go hand in hand to further strengthen the company
Yunnan Baiyao (000538) 2023 Third Quarter Report Performance Review: Steady Profit Growth After Removing Disturbances Continues to Strengthen R&D Innovation
Guide to this report: The company released its three-quarter report for 2023. The overall performance was in line with expectations. Revenue and profit increased steadily after removing disruptive factors, strengthened R&D investment and talent introduction, and helped new development in the future. Investment points: Maintain an “excess” rating.
Express News | Yunnan Baiyao: Yunnan State-owned Equity Operation and Management Co., Ltd. continues to introduce China Life Insurance Asset Management Co., Ltd. to increase capital by 11 billion yuan.
Yunnan Baiyao (000538.SZ): In the first half of the year, Yunnan Baiyao aerosol contributed more than 900 million yuan in revenue, an increase of 18.20% over the previous year
Gelonghui November 2 | Yunnan Baiyao (000538.SZ) was surveyed by specific subjects on October 31, 2023. Regarding “Please tell me about the sales situation of Yunnan Baiyao core series products and other brands of traditional Chinese medicine in the first half of the year”, the company replied that in the first half of 2023, Yunnan Baiyao Aerosol contributed more than 900 million yuan in revenue, an increase of 18.20% over the previous year; the revenue of Yunnan Baiyao Cream and Yunnan Baiyao capsules continued to grow. In terms of other brands of traditional Chinese medicine products, seizing market expansion opportunities, the business and OTC sectors have expanded and increased the scope of multiple products through medium output and product-driven methods. Cold-like products
Yunnan Baiyao (000538): Revenue side continues to grow steadily, Q3 performance is in line with expectations
Core Opinion On the evening of October 30, the company released its report for the third quarter of 2023. Among them, Q3 achieved operating income of 9.379 billion yuan in a single quarter, an increase of 5.40% over the previous year; net profit of 1.295 billion yuan was realized, same as
Yunnan Baiyao (000538): Performance slightly exceeded expectations, and gross margin increased year-on-year in the third quarter
The 1-3Q performance slightly exceeded our expectations. The company announced 1-3Q23 results: operating income was 29.689 billion yuan, up 10.3% year on year; net profit was 4.123 billion yuan, up 78.9% year on year, not net
Yunnan Baiyao (000538) 2023 Third Quarter Report Review: Steady Growth in Performance Continues to Increase Investment in R&D
Matters: The company released its three-quarter report for 2023. The company's revenue was 29.689 billion yuan (+10.3%), net profit was 4.123 billion yuan (+78.9%), and net profit after deducting non-return mother was 3.853 billion yuan
Yunnan Baiyao (000538): Continued good trends in the third quarter disrupted expectations for growth
Investment highlights The third quarter continued the positive trend of the first half of the year. The first three quarters of 2023 achieved operating income of 29.689 billion yuan, an increase of 10.3% over the previous year, and net profit of 4.123 billion yuan, an increase of 78.9% over the previous year, a non-return
Yunnan Baiyao's Profit Jumps 61% in Q3 as Revenue Rises 5%
Yunnan Baiyao Group (SHE:000538) posted a 61.1% year-over-year jump in net profit in the third quarter of the year as revenue rose 5.4% from a year earlier. Net profit stood at 1.3 billion yuan, or 0.
Yunnan Baiyao (000538): Focus on the main business and strengthen R&D
Event: In the first three quarters of 2023, the company's revenue for the first three quarters was 29.69 billion yuan (+10.3%), net profit was 4.12 billion yuan (+78.9%), net profit after deducting non-return net profit was 3.85 billion yuan (+42.5%). toothpaste market
Express News | Yunnan Baiyao: Net profit for the third quarter of 2023 was 1,295 billion yuan, up 61.05% year on year
Yunnan Baiyao (000538.SZ): Yunnan Baiyao toothpaste still maintains a trend exceeding the average growth trend of the toothpaste industry, achieving a 25% market share
Glonghui, Oct. 19, 丨 Yunnan Baiyao (000538.SZ) said on the investor interactive platform that in the first half of 2023, the health products division achieved main business revenue of 3,245 billion yuan, an increase of 0.81% over the previous year, and achieved many breakthroughs in both the oral care sector and the anti-peeling care sector. In the oral care sector, Yunnan Baiyao toothpaste still maintains a trend exceeding the average growth trend of the toothpaste industry, achieving a market share of 25% (data source: Nielsen retail research data YTD2306), and continues to hold the highest market share in the industry.
Yunnan Baiyao (000538.SZ): It has houttuynia cordata wall-breaking powder, which has the effects of clearing heat and detoxifying, purifying and draining pus, and diuretic and gonorrhea
Glonghui, Oct. 19 | Yunnan Baiyao (000538.SZ) said on the investor interactive platform that Yunnan Baiyao has houttuyao wall-breaking powder, which has the effects of clearing heat and detoxifying, purifying and draining pus, and diuretic.
YNBY International Plans Year-End Date Change
The board of YNBY International (HKG:0030) decided to change the company's financial year-end date to Dec. 31 from March 31 to align with that of its controlling shareholder, Yunnan Baiyao Group (SHE:
Zhende Medical and Yunnan Baiyao Taibang reached a strategic cooperation
Gelonghui September 24 | Zhende Medical announced that it has officially launched a strategic cooperation with Yunnan Baiyao Taibang to jointly open a new chapter of pharmaceutical cooperation with many domestic pharmacy chains. The two sides use protective gear as the basis for cooperation. In the future, they will carry out more in-depth cooperation in more fields to provide consumers with better and more product choices.
Research Report Nuggets 丨 Haitong Securities: Yunnan Baiyao's four major divisions are growing steadily, and multi-core categories are rapidly expanding
Gelonghui, September 21 | According to the Haitong Securities Research Report, Yunnan Baiyao (000538.SZ) continues to deepen its digital strategic transformation, the brand value of traditional Chinese medicine resources continues to increase, and core categories continue to expand. The company was given 30-35X PE in 2023, corresponding to a reasonable value range of 71.70-83.65 yuan, and maintained a “superior to market” rating. In the first half of the year, the company's four major business divisions grew steadily, and the number of multi-core categories was rapidly expanded. Among them, the Pharmaceutical Division achieved revenue of 3.852 billion yuan in the first half of the year, an increase of 14.63% over the previous year. Among Baiyao's core series of products, the Yunnan Baiyao Aerosol Market
Yunnan Baiyao (000538): Steady growth of the four major divisions and deepening the layout of emerging business units
incident. The company released its semi-annual report for 2023. In the first half of '23, the company achieved operating income of 20.309 billion yuan (+12.73%) and net profit of 2,828 billion yuan (+88.47%), after deducting non-attributable net profit
Comparing with Yunnan Baiyao, Guangzhou Baiyunshan also needs to sell toothpaste
GLONGHUI, September 19 | According to Beijing Commercial Daily, another traditional Chinese medicine company has entered the toothpaste market. According to reports, Guangzhou Baiyunshan Pharmaceutical Group Co., Ltd., a subsidiary of Guangzhou Pharmaceutical Group, and Meichen Group, a toothpaste manufacturer, have jointly formed Guangzhou Baiyun Toothpaste Company. Three new series of Guangzhou Pharmaceutical Baiyun toothpaste products have also been officially unveiled. Against the backdrop of a slowdown in revenue growth in the health business sector, Guangzhou Pharmaceutical Baiyunshan may need new growth points. The relevant person in charge of Guangzhou Pharmaceutical Group said that the product position of Guangzhou Pharmaceutical Baiyun toothpaste is “to remove bacteria and clean the fire, and is as white as a cloud”. This time, it has launched three series of toothpastes: high-end, fashionable, and classic. Introducing pump packs and tubes in stylish packaging
Express News | Yunnan Baiyao is currently traded at a discount of 30.144,500 yuan, with a discount rate of 4.51%